Pacylex recently reported results at the Canadian Association of Radiation Oncology highlighting that zelenirstat was more effective than clinically used radiosensitizers
A myristoylation inhibition gene expression signature, MISS-91 (Myristoylation Inhibitors Sensitivity Signature), will be presented at the European Association for Cancer Research (EACR) 2023 Congress.
Pacylex will present at ASH 2022 that Phase I clinical trial data that PCLX-001 is safe in patients at drug levels that kill AML cell lines in vitro and patient AML cells ex vivo.
Pacylex has now safely completed 4 dose cohorts and exceeded the predicted target drug exposure levels in patients based on in vitro testing of PCLX-001 with leukemia and lymphoma patient cells and cell lines.
Pacylex announces that their lead compound, PCLX-001, is granted Orphan Drug Designation for “treatment of patients with acute myeloid leukemia" by the U.S. Food and Drug Administration (FDA).
US Department of Defense Awards $1.4 million for AML Study. This study in AML patients at MD Anderson will be the first clinical study of PCLX-001 in the US.
New data on PCLX-001 being presented at AACR showing the potential for N-myristoylation inhibition to treat for AML with in vitro and animal model data: PCLX-001 dramatically reduces AML stem cells in the bone marrow.
Pacylex Pharmaceuticals Announces Publication in Current Oncology of First Clinical Experience with an N-myristoyltransferase (NMT) inhibitor in a Patient with Diffuse Large B-cell Lymphoma (DLBCL)
Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Patients. First clinical patient dosed at Cross Cancer Institute, Edmonton.